Top

Published in:

Open Access 01-05-2014

New perspectives of nitric oxide donors in cardiac arrest and cardiopulmonary resuscitation treatment

Authors: Peter Kruzliak, Olga Pechanova, Tomas Kara

Published in: Heart Failure Reviews | Issue 3/2014

Abstract

Nitric oxide (NO) is often used to treat heart failure accompanied with pulmonary edema. According to present knowledge, however, NO donors are contraindicated when systolic blood pressure is less than 90 mmHg. Based on recent findings and our own clinical experience, we formulated a hypothesis about the new breakthrough complex lifesaving effects of NO donors in patients with cardiac arrest and cardiopulmonary resuscitation therapy. It includes a direct hemodynamic effect of NO donors mediated through vasodilation of coronary arteries in cooperation with improvement of cardiac function and cardiac output through reversible inhibition of mitochondrial complex I and mitochondrial NO synthase, followed by reduction in reactive oxygen species and correction of myocardial stunning. Simultaneously, an increase in vascular sensitivity to sympathetic stimulation could lead to an increase in diastolic blood pressure. Confirmation of this hypothesis in clinical practice would mean a milestone in the treatment for cardiac arrest and cardiopulmonary resuscitation.

Kelly RA, Balligand J-L, Smith TW (1996) Nitric oxide and cardiac function. Circ Res 79:363–380PubMedCrossRef

Akiyama K, Suzuki H, Grant P et al (1997) Oxidation products of nitric oxide, NO2 and NO3, in plasma after experimental myocardial infarction. J Mol Cell Cardiol 29:1–9PubMedCrossRef

Lecour S, Maupoil V, Zeller M et al (2001) Levels of nitric oxide in the heart after experimental myocardial ischaemia. J Cardiovasc Pharmacol 37:55–63PubMedCrossRef

Beckman JS, Crow JP (1992) Pathological implications of nitric oxide, superoxide and peroxynitrite formation. Biochem Soc Trans 21:330–334

Jones SP, Girod WG, Palazzo AJ et al (1999) Myocardial ischemia-reperfusion injury is exacerbated in the absence of endothelial nitric oxide synthase. Am J Physiol 276:1567–1573

Kleinbongard P, Dejam A, Lauer T et al (2006) Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. Free Radic Biol Med 40:295–302PubMedCrossRef

Pechanova O, Simko F (2009) Chronic antioxidant therapy fails to ameliorate hypertension: potential mechanisms behind. J Hypertens Suppl 27:S32–S36PubMedCrossRef

Levi RC, Alloatti G, Fischmeister R (1989) Cyclic cGMP regulates the Ca-channel current in guinea pig ventricular myocytes. Eur J Physiol 13:685–687CrossRef

Ballgand JL, Kelly RA, Marsden PA et al (1993) Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA 90:347–351CrossRef

10.

Weiss HR, Rodriguez E, Tse J et al (1994) Effect of increased myocardial cyclic GMP induced by GMP phosphodiesterase inhibition on oxygen consumption and supply of rabbit hearts. Clin Exp Pharmacol Physiol 21:607–614PubMedCrossRef

11.

Shen W, Hintze TW, Wolin MS (1995) Nitric Oxide: an important signaling mechanism between vascular endothelium and parenchymal cells in the regulation of oxygen consumption. Circulation 92:3505–3512PubMedCrossRef

12.

Shinbo A, Iijima T (1997) Potentiation by nitric oxide of the ATP-sensitive K current induced by K channel openers in guinea-pig ventricular cells. Br J Pharmacol 120:1568–1574PubMedCentralPubMedCrossRef

13.

Murphy ME, Brayden JE (1995) Nitric Oxide hyperpolarizes rabbit mesenteric arteries via ATP-sensitive potassium channels. J Physiol (Lond) 486:47–58

14.

Shinmura K, Xuan Y-T, Tang X-L et al (2002) Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. Circ Res 90:602–608PubMedCrossRef

15.

Shinmura K, Tang X-L, Wang Y et al (2000) Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA 97:10197–10202PubMedCentralPubMedCrossRef

16.

Villa LM, Salas E, Darley-Usmar VM et al (1994) Peroxynitrite induces both vasodilatation and impaired vascular relaxation in the isolated perfused rat heart. Proc Natl Acad Sci USA 91:12383–12387PubMedCentralPubMedCrossRef

17.

Weyrich AS, Ma XL, Lefer AM (1992) The role of l-arginine in ameliorating reperfusion injury after myocardial ischemia in the cat. Circulation 86:279–288PubMedCrossRef

18.

Pabla R, Buda AJ, Flynn DM et al (1996) Nitric oxide attenuates neutrophil-mediated myocardial contractile dysfunction after ischemia and reperfusion. Circ Res 78:65–72PubMedCrossRef

19.

Yamauchi-Takihara K, Ihara Y, Ogata A et al (1995) Hypoxic stress induces cardiac myocyte–derived interleukin-6. Circulation 91:1520–1524PubMedCrossRef

20.

Vila-Petroff MG, Younes A, Egan J et al (1999) Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ Res 84:1020–1031PubMedCrossRef

21.

Massion PB, Balligand JL (2003) Modulation of cardiac contraction, relaxation and rate by the endothelial nitric oxide synthase (eNOS): lessons from genetically modified mice. J Physiol 546:63–75PubMedCentralPubMedCrossRef

22.

Kojda G, Kottenberg K (1999) Regulation of basal myocardial function by NO. Cardiovasc Res 41:514–523PubMedCrossRef

23.

Shah AM, Spurgeon HA, Sollott SJ, Talo A, Lakatta EG (1994) 8-Bromo-cGMP reduces the myofilament response to Ca²⁺ in intact cardiac myocytes. Circ Res 74:970–978PubMedCrossRef

24.

Naim KL, Rabindranauth P, Weiss HR et al (1998) Positive inotropy due to lowering cyclic GMP is also mediated by increase in cyclic AMP in control and hypertrophic hearts. Can. J. Physiol Pharmacol 76:605–612CrossRef

25.

Post H, Schulz R, Gres P, Heusch G (2001) No involvement of nitric oxide in the limitation of β-adrenergic inotropic responsiveness during ischemia. Am J Physiol Heart Circ Physiol 281:2392–2397

26.

Kanner J, Harel S, Granit R (1991) Nitric oxide as an antioxidant. Arch Biochem Biophys 289:130–136PubMedCrossRef

27.

Zimmerman BJ, Grisham MB, Granger DN (1990) Role of oxidants in ischemia/reperfusion-induced granulocyte infiltration. Am J Physiol 258:185–190

28.

Clancy R, Leszczynska-Piziak J, Abramson S (1992) Nitric oxide, and endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest 90:1116–1121PubMedCentralPubMedCrossRef

29.

Boddupalli CS, Ghosh S, Rahim SS et al (2007) Nitric oxide inhibits interleukin-12 p40 through p38 MAPK-mediated regulation of calmodulin and c-rel. Free Radic Biol Med 42:686–697PubMedCrossRef

30.

Hinder F, Stubbe HD, Van Aken H et al (1999) Role of nitric oxide in sepsis-associated pulmonary edema. Am J Respir Crit Care Med 159:252–257PubMedCrossRef

31.

Persson J, Ekelund U, Grande PO (2003) Endogenous nitric oxide reduces microvascular permeability and tissue oedema during exercise in cat skeletal muscle. J Vasc Res 40:538–546PubMedCrossRef

32.

Banick PD, Chen QP, Xu YA et al (1997) Nitric oxide inhibits neutrophil b2 integrin function by inhibiting membrane-associated cyclic GMP synthesis. J Cell Physiol 172:12–24PubMedCrossRef

33.

Kubes P, Suzuki M, Granger DN (1991) Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 88:4651–4655PubMedCentralPubMedCrossRef

34.

Wallace JL, Ignarro LJ, Fiorucci S (2002) Potential cardio-protective actions of nitric oxidereleasing aspirin. Nat Rev Drug Discov 1:375–382PubMedCrossRef

35.

Wallace JL, Vergnolle N, Muscara MN et al (1999) Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. Gastroenterology 117:557–566PubMedCrossRef

36.

May GR, Crook P, Moore PK et al (1991) The role of nitric oxide as an endogenous regulator of platelet and neutrophil activation within the pulmonary circulation of the rabbit. Br J Pharmacol 102:759–763PubMedCentralPubMedCrossRef

37.

Rubanyi GM, Ho EH, Cantor EH et al (1991) Cytoprotective function of nitric oxide: inactivation of superoxide radicals produced by human leukocytes. Biochem Biophys Res Commun 181:1392–1397PubMedCrossRef

38.

Katsuyama K, Shichiri M, Marumo F et al (1997) NO inhibits cytokine-induced iNOS expression and NF-kappaB activation by interfering with phosphorylation and degradation human endothelial cells by nitric oxide. Am J Physiol 273:740–746

39.

Armstead VE, Minchenko AG, Schuhl RA et al (1997) Regulation of P-selectin expression in human endothelial cells by nitric oxide. Am J Physiol 273:H740–H746

40.

Ahluwalia A, Foster P, Scotland RS et al (2004) Anti-inflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci USA 101:1386–1391PubMedCentralPubMedCrossRef

41.

Herzog WR, Vogel RA, Schlossberg ML et al (1997) Short-term low dose intracoronary diltiazem administered at the onset of reperfusion reduces myocardial infarct size. Int J Cardiol 59:21–27PubMedCrossRef

42.

Mukherjee SB, Das M, Sudhandiran G et al (2002) Increase in cytosolic Ca²⁺ levels through the activation of non-selective cation channels induced by oxidative stress causes mitochondrial depolarization leading to apoptosis-like death in leishmania donovani promastigotes. J Biol Chem 277:24717–24727PubMedCrossRef

43.

Piper HM, Garcia-Dorado D (1999) Prime cause of rapid cardiomyocyte death during reperfusion. Ann Thorac Surg 68:1913–1919PubMedCrossRef

44.

Piper HM, Garcia-Dorado D, Ovize M (1998) A fresh look at reperfusion injury. Cardiovasc Res 38:291–300PubMedCrossRef

45.

Halestrap AP, Clarke SJ, Javadov SA (2004) Mitochondrial permeability transition pore opening during myocardial reperfusion—a target for cardioprotection. Cardiovasc Res 61:372–385PubMedCrossRef

46.

Taimor G, Hofstaetter B, Piper HM (2000) Apoptosis induction by nitric oxide in adult cardiomyocytes via cGMP-signaling and its impairment after simulated ischemia. Cardiovasc Res 45:588–594PubMedCrossRef

47.

Hofstaetter B, Taimor G, Inserte J et al (2002) Inhibition of apoptotic responses after ischemic stress in isolated hearts and cardiomyocytes. Basic Res Cardiol 97:479–488PubMedCrossRef

48.

Leist M, Single B, Naumann H et al (1999) Inhibition of mitochondrial ATP generation by nitric oxide switches apoptosis to necrosis. Exp Cell Res 249:396–403PubMedCrossRef

49.

Han O, Joe KH, Kim SW et al (2001) Involvement of p38 mitogen-activated protein kinase and apoptosis signal-regulating kinase-1 in nitric oxide-induced cell death in PC12 cells. Neurochem Res 26:525–532PubMedCrossRef

50.

Taimor G, Rakow A, Piper HM (2001) Transcription activator protein 1 (AP-1) mediates NO induced apoptosis of adult cardiomyocytes. FASEB J 15:2518–2520PubMed

51.

Kim Y-M, de Vera ME, Watkins SC et al (1997) Nitric oxide protects cultured rat hepatocytes from tumour necrosis factor-á-induced apoptosis by inducing HSP 70 expression. J Biol Chem 272:1402–1411PubMedCrossRef

52.

Sanders DB, Larson DF, Hunter K et al (2001) Comparison of tumor necrosis factor-alpha effect on the expression of iNOS in macrophage and cardiac myocytes. Perfusion 16:67–74PubMedCrossRef

53.

Brown GC, Borutaite V (2004) Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols. Biochim Biophys Acta 1658:44–49PubMedCrossRef

54.

Bryan NS, Calvert JW, Elrod JW et al (2007) Dietary nitrite supplementation protects against myocardial ischemia-reperfusion injury. Proc Natl Acad Sci USA 104:19144–19149PubMedCentralPubMedCrossRef

55.

Shiva S, Brookes PS, Patel RP et al (2001) Nitric oxide partitioning into mitochondrial membranes and the control of respiration at cytochrome c oxidase. Proc Natl Acad Sci USA 98:7212–7217PubMedCentralPubMedCrossRef

56.

Burwell LS, Brookes PS (2008) Mitochondria as a target for the cardioprotective effects of nitric oxide in ischemia-reperfusion injury. Antioxid Redox Signal 10:579–599PubMedCrossRef

57.

Minamishima S, Kida K, Tokuda K et al (2011) Inhaled nitric oxide improves outcomes after successful cardiopulmonary resuscitation in mice. Circulation 124:1645–1653PubMedCentralPubMedCrossRef

58.

Brown GC (1999) Nitric oxide and mitochondrial respiration. Biochim Biophys Acta 1411:351–369PubMedCrossRef

59.

Rakhit RD, Edwards RJ, Mockridge JW et al (2000) Nitric oxide induced cardioprotection in cultured rat ventricular myocytes. Am J Physiol Heart Circ Physiol 278:1211–1217

60.

Boengler K, Dodoni G, Ruiz-Meana M et al (2005) Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic preconditioning. Cardiovasc Res 67:234–244PubMedCrossRef

61.

Mehlhorn U, Bloch W, Krahwinkel A et al (2000) Activation of myocardial constitutive nitric oxide synthase during coronary artery surgery. Eur J Cardiothorac Surg 17:305–311PubMedCrossRef

62.

Schulz R, Boengler K, Totzeck A et al (2007) Connexin 43 in ischemic pre- and postconditioning. Heart Fail Rev 12:261–266PubMedCrossRef

63.

Stamler JS, Loh E, Roddy MA et al (1994) Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 89:2035–2040PubMedCrossRef

64.

Ardehali H, Chen Z, Ko Y et al (2004) Multiprotein complex containing succinate dehydrogenase confers mitochondrial ATP-sensitive K channel activity. Proc Natl Acad Sci USA 101:11880–11885PubMedCentralPubMedCrossRef

65.

Gross GJ, Peart JN (2003) KATP channels and myocardial preconditioning: an update. Am J Physiol Heart Circ Physiol 285:921–930

66.

Penna C, Rastaldo R, Mancardi D et al (2006) Post-conditioning induced cardioprotection requires signaling through a redox-sensitive mechanism, mitochondrial ATP-sensitive K channel and protein kinase C activation. Basic Res Cardiol 101:180–189PubMedCrossRef

67.

Sasaki N, Sato T, Ohler A et al (2000) Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation 101(4):439–445PubMedCrossRef

68.

Bell RM, Maddock HL, Yellon DM (2003) The cardioprotective and mitochondrial depolarising properties of exogenous nitric oxide in mouse heart. Cardiovasc Res 57:405–415PubMedCrossRef

69.

Shen AC, Jennings RB (1972) Kinetics of calcium accumulation in acute myocardial ischemic injury. Am J Pathol 67:441–452PubMedCentralPubMed

70.

Allen SP, Darley-Usmar VM, McCormack JG et al (1993) Changes in mitochondrial matrix free calcium in perfused rat hearts subjected to hypoxia-reoxygenation. J Mol Cell Cardiol 25:949–958PubMedCrossRef

71.

Wang Y, Ashraf M (1999) Role of protein kinase C in mitochondrial KATP channel-mediated protection against Ca overload injury in rat myocardium. Circ Res 84:1156–1165PubMedCrossRef

72.

Holmuhamedov EL, Wang L, Terzic A (1999) ATP-sensitive K1 channel openers prevent Ca21 overload in rat cardiac mitochondria. J Physiol (Lond) 519:347–360CrossRef

73.

Borutaite V, Morkuniene R, Brown GC (1999) Release of cytochrome c from heart mitochondria is induced by high Ca21 and peroxynitrite and is responsible for Ca(21)-induced inhibition of substrate oxidation. Biochim Biophys Acta 1453:41–48PubMedCrossRef

74.

Di Lisa F, Menabo R, Canton M et al (2001) Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD1 and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem 276:2571–2575PubMedCrossRef

75.

Brookes PS, Salinas EP, Darley-Usmar K et al (2000) Concentration-dependent effects of nitric oxide on mitochondrial permeability transition and cytochrome c release. J Biol Chem 275:20474–20479PubMedCrossRef

76.

Di Lisa F, Canton M, Menabo R, Kaludercic N, Bernardi P (2007) Mitochondria and cardioprotection. Heart Fail Rev 12:249–260PubMedCrossRef

77.

Griffiths EJ, Halestrap AP (1995) Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 307:93–98PubMedCentralPubMed

78.

Martinou JC, Green DR (2001) Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2:63–67PubMedCrossRef

79.

Zimmermann KC, Green DR (2001) How cells die: apoptosis pathways. J Allergy Clin Immunol 108:S99–S103PubMedCrossRef

80.

Griffiths EJ, Halestrap AP (1993) Protection by cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol 25:1461–1469PubMedCrossRef

81.

Hausenloy D, Wynne A, Duchen M et al (2004) Transient mitochondrial permeability transition pore opening mediates preconditioning-induced protection. Circulation 109:1714–1717PubMedCrossRef

82.

Feng Q, Lu X, Jones DL et al (2001) Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation 104:700–704PubMedCrossRef

83.

Nakano A, Liu GS, Heusch G et al (2000) Exogenous nitric oxide can trigger a preconditioned state through a free radical mechanism, but endogenous nitric oxide is not a trigger of classical ischemic preconditioning. J Mol Cell Cardiol 32:1159–1167PubMedCrossRef

84.

Franciosa JA, Limas CJ, Guiha NH et al (1972) Improved left ventricular function during nitroprusside infusion in acute myocardial infarction. Lancet 1:650–654PubMedCrossRef

85.

Bayley S, Valentine H, Bennett ED (1984) The haemodynamic responses to incremental doses of intravenous nitroglycerin in left ventricular failure. Intensive Care Med 10:139–145PubMedCrossRef

86.

Cotter G, Metzkor E, Kaluski E et al (1998) Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 351:389–393PubMedCrossRef

Title: New perspectives of nitric oxide donors in cardiac arrest and cardiopulmonary resuscitation treatment
Authors: Peter Kruzliak
Olga Pechanova
Tomas Kara
Publication date: 01-05-2014
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 3/2014
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-013-9397-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The STEP trials

Springer Medicine

New perspectives of nitric oxide donors in cardiac arrest and cardiopulmonary resuscitation treatment

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Atrial fibrillation in heart failure: drug therapies for rate and rhythm control

Obesity as a risk factor for poor neurocognitive outcomes in older adults with heart failure

Atrial fibrillation and heart failure: intersecting populations, morbidities, and mortality

Functional mitral regurgitation: a 30-year unresolved surgical journey from valve replacement to complex valve repairs

Combined management of atrial fibrillation and heart failure: case studies

Clinical use of novel biomarkers in heart failure: towards personalized medicine

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page